Hemophilia A — Efficacy and Safety of IL-11 in DDAVP Unresponsive
Citation(s)
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP